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Abstract
Bipolar disorder is one of the most common and devastating psychiatric disorders whose mechanisms remain largely
unknown. Despite a strong genetic contribution demonstrated by twin and adoption studies, a polygenic background
influences this multifactorial and heterogeneous psychiatric disorder. To identify susceptibility genes on a severe and more
familial sub-form of the disease, we conducted a genome-wide association study focused on 211 patients of French origin
with an early age at onset and 1,719 controls, and then replicated our data on a German sample of 159 patients with early-
onset bipolar disorder and 998 controls. Replication study and subsequent meta-analysis revealed two genes encoding
proteins involved in phosphoinositide signalling pathway (PLEKHA5 and PLCXD3). We performed additional replication
studies in two datasets from the WTCCC (764 patients and 2,938 controls) and the GAIN-TGen cohorts (1,524 patients and
1,436 controls) and found nominal P-values both in the PLCXD3 and PLEKHA5 loci with the WTCCC sample. In addition, we
identified in the French cohort one affected individual with a deletion at the PLCXD3 locus and another one carrying a
missense variation in PLCXD3 (p.R93H), both supporting a role of the phosphatidylinositol pathway in early-onset bipolar
disorder vulnerability. Although the current nominally significant findings should be interpreted with caution and need
replication in independent cohorts, this study supports the strategy to combine genetic approaches to determine the
molecular mechanisms underlying bipolar disorder.
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Introduction
Numerous genome-wide association (GWA) studies have
recently been performed on bipolar disorder (BD), but few signals
were replicated and meta-analyses identified only a couple of
associated genes, such as CACNA1C, ODZ4 and NCAN, with a
small effect size [1–4]. Although convergent evidences argue in
favour of a role for these genes in vulnerability to BD [5–9], more
extensive studies suggest it might be involved in other psychiatric
disorders [3,10,11]. The difficulty to identify susceptibility genes
specific to BD could be due to the ethnic heterogeneity, as a
consequence of the huge number of patients and controls required
to get genome-wide significant signals, or to the clinical and a
genetic heterogeneity of the DSM-IV ‘‘bipolar disorder’’ entity.
In the current study, we focused on patients with BD selected
with an early age at onset, a clinical characteristic known to
identify a subgroup of patients with a higher morbid risk for BD in
relatives [12–17]. We then compared these data to those observed
in two previously published GWA studies of BD, conducted by the
Wellcome Trust Case Control Consortium (WTCCC) [18] and
the Genetic Association Information Network Bipolar Sample
(GAIN-BP) [19]. Finally, we screened our regions of interest for
rare variants, suspected to have a larger effect size, and suggested
the importance of combined approaches in the identification of
vulnerability genes to BD.
Materials and Methods
Ethics Statement
Protocols and procedures were approved by the research ethics
board of the Pitie´-Salpeˆtrie`re Hospital in Paris for the French
sample and the ethics committees of the Faculties of Medicine at
the Universities of Bonn and Mannheim/Heidelberg for the
German sample. Written informed consent was obtained from all
subjects prior to study participation.
Sample
French sample. Two hundred and twenty patients of French
descent with at least three grandparents from mainland France
were collected through a French national network for mental
health (Fondation FondaMental) in three university-affiliated
psychiatry departments (Paris-Cre´teil, Bordeaux and Nancy) as
previously described [12]. All patients met DSM-IV criteria [20]
for BD type I (N= 172), type II (N=46) or BD not otherwise
specified (N= 2) before the age of 22. The age at onset was defined
by the first mood episode (depressive, manic or hypomanic) and
was retrospectively assessed using medical case notes and
information obtained with the Diagnostic Interview for Genetic
Studies (DIGS) [21]. The threshold of 22 was chosen on the basis
of previous admixture analyses [16,22–25].
German sample. One hundred and sixty-seven German
patients were recruited from consecutive admissions to the
psychiatric inpatient units of the Central Institute of Mental
Health in Mannheim and the Department of Psychiatry and
Psychotherapy of the University of Bonn (BOMA bipolar study).
These patients received a lifetime diagnosis of BD type I based on
DSM-IV criteria and had an age at onset lower than 22.
Control population. Genotyping data from 1,823 French
controls and 629 German controls were provided by the Centre
National de Ge´notypage (CNG, Evry, France). These samples were
previously collected and were not screened for psychiatric
disorders. They have been genotyped for association and
population studies as described elsewhere [26] and permission to
use them were obtained from the original investigators. DNA from
380 additional German controls were collected in the above
mentioned German hospitals. An additional sample of 293
unaffected French controls screened for personal history of
psychiatric disorders using the DIGS has been screened for
mutation in the PLCXD3 exon 2, in order to determine the
specificity of the p.R93H mutation.
DNA extraction and genotyping
DNA was isolated from lymphocytes either directly from venous
blood sample or after transformation by Epstein Barr virus.
Isolation was performed by salting-out with saturated sodium
chloride solution [27]. French and German cases were genotyped
at the CNG, using HumanHap550 or Human 610-Quad
BeadArrays and the Infinium II assay (Illumina, San Diego, CA,
USA). Control samples were genotyped on HumanHap300
(N= 2,503) or on HumanHap550 BeadArrays (N=380). In order
to determine whether the use of multiple arrays might result in a
population stratification, we performed a multidimensional scaling
analysis based on pairwise identity-by-state distance between pairs
of individuals. The good clustering of all individuals showed that
there was no stratification due to the use of multiple arrays (Figure
S1 in File S1).
Quality control criteria
All samples were passed through the standard quality-control
procedures followed at the CNG for GWA studies, as described
elsewhere [26]. For the French population, the quality control was
performed using the PLINK toolset [28] on a total of 317,131
commons SNPs genotyped in 2,043 DNA samples (Table S1 in
File S1). We removed monomorphic SNPs, as those with a minor
allele frequency (MAF) lower than 0.01 and SNPs with a call rate
lower than 0.97. We performed a missing chi-square test that
compares, for each SNP, missingness between cases and controls
and excluded SNPs with P,1023. Then, we removed SNPs that
did not show Hardy-Weinberg proportions in controls, using a
significant threshold at P,1023. In parallel, we removed male
samples with more than 0.5% or female samples with less than
20% heterozygous markers on the X chromosome and individuals
with a call rate lower than 0.97. We estimated the average
genome-wide identity-by-state (IBS) sharing between individuals
and analysed the clustering using a multidimensional scaling
(MDS) plot. Hence, we excluded 15 individuals (3 cases and 12
controls) with a low level of identity. After pruning, the final data
set consisted in 261,525 SNPs genotyped in 1,930 individuals (211
cases and 1,719 controls) that were used for association study.
Identical quality control criteria were used for the replication
sample from Germany (Table S1 in File S1) and MDS plot showed
6 controls to be removed. This led to a final data set of 288,167
SNPs and 1,157 individuals (159 patients and 998 controls).
Association analysis
Basic case/control association analyses were performed using
the PLINK software v1.07 [28]. A haplotype analysis was
performed on the two most associated regions using sliding
windows of two to five SNPs shifting by one SNP at a time. We
tested for case/control haplotype-based association using a chi-
square test with one degree of freedom. Only window with best P-
values are reported for each region. Imputation data were based
on the 3,967,651 SNPs genotyped in 90 subjects of the CEU
population of the HapMap project (http://www.hapmap.org).
Imputation was performed using PLINK and consisted in
estimating the allele frequencies of an ungenotyped SNP based
on its surrounding haplotypic background.
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Genotyping data from the WTCCC [18] and the GAIN-TGen
collection [19] were provided for BD patients with an age at onset
lower than 22 and for controls. In the WTCCC, BD was defined
according to Research Diagnostic Criteria [29] and included BD
type I, type II, schizoaffective disorders and manic disorders. The
WTCCC sample was genotyped on Affymetrix 500K array,
containing only few SNPs in common with the Illumina arrays
used in other samples. Thus, the genotype correlation data were
obtained for SNPs within a 1 Mbp window, based on individuals
and SNPs in the CEU HapMap filtered set (http://www.hapmap.
org) and the 2,938 WTCCC control sample combined [18]. An
association test between 764 early-onset patients and 2,938
controls was performed, using SNPs with a genotyped correlation
higher than 0.2 with associated SNPs at P,561025 identified
through the meta-analysis.
All patients from the GAIN-TGen cohort met DSM-IV criteria
for BD type I. Imputed data from the GAIN-TGen bipolar case-
control sample [30] were obtained, using the MACH software
with phased haplotypes from the 60 HapMap-CEU founders
(release 22). Allele frequencies of 15 SNPs out of the 16 associated
SNPs at P,561025, were compared between 1,524 patients with
an early age at onset and 1,436 controls.
A flow chart summarizing all steps of the genetic analysis is
shown on the Figure S2 in File S1.
Detection of copy number variations
Copy number variations were detected by fluorescence level
comparison through the chromosome, using the SnipPeep
software (R. Toro, Pasteur Institute, France). The deletion in
PLCXD3 was confirmed by quantitative PCR analysis using one
internal and two external couples of primers and Mesa Green
qPCR master mix plus (Eurogentec, Liege, Belgium). PCR were
performed and run in a Mastercycler ep realplex2S (Eppendorf,
Hamburg, Germany) for the deleted patient and two unaffected
controls, known to have no deletion in the regions under study.
Each real-time PCR was performed in triplicate and assessed by
comparing Ct at a determined threshold between the three
amplicons and the three individuals.
Mutation screening in PLCXD3
The PLCXD3 coding regions were amplified for 334 French
subjects with BD, sequenced by the Sanger’s method using the
BigDye terminator v3.1 cycle sequencing kit (Life Technologies,
Carlsbad, CA, U.S.A.) and run on a 16-Capillary ABI PRISM
3130xl genetic analyzer. The PLCXD3 exon 2 was sequenced for
293 unaffected French controls. All primers used for PCR
amplifications and sequence analyses are available on request.
Results
Analysis of a French cohort
We carried out an association study on 211 patients with early-
onset BD of French origin and 1,719 matched controls, who have
been genotyped on an Illumina platform with 261,525 single
nucleotide polymorphisms (SNPs) passing quality control. The
estimation of an inflation factor [31] showed a good genetic
homogeneity in our sample (l=1.03), suggesting that no
correction for genomic control was needed. According to the
genome-wide significance threshold of P=561028, no significant
difference in allele frequencies was observed in our sample, but 17
SNPs showed a nominal P,561025 (Table S2 in File S1),
suggesting these loci may be associated with vulnerability to early-
onset forms of BD. Interestingly, the lowest P-value (rs10096683,
P=4.1161026, OR=2.26), was observed for a SNP located on
chromosome 8p22, a region that has previously been associated
with schizophrenia [32–35] and suicide behaviour in patients with
recurrent major depression [36].
Replication on a German cohort
Next, we selected 14,037 SNPs with a P,0.05 to perform a
replication study on an independent sample of 159 German
subjects with an early-onset BD and 998 matched controls (Table
S1 in File S1). Again, a good genetic homogeneity (l=1.04) was
observed after quality control for this sample. Out of the 14,037
SNPs previously selected, 13,734 were genotyped in the German
sample, and 739 showed a P,0.05, showing a significant over-
representation (P,0.03) of nominally significant P-values. The
most associated SNP in the German sample was located on
chromosome 12 upstream to the PLEKHA5 gene (rs2970836,
P=5.361026, OR=1.76).
Meta-analysis on the French and the German cohorts
We subsequently performed a meta-analysis, combining data
from the French and the German cohorts, yielding a sample of 370
patients with early-onset BD and 2,717 controls. Again, no locus
reaches the genome-wide significant threshold. The largest
difference in allele frequencies between cases and controls was
observed for chromosome 12 (rs2961365, Pmeta = 1.6610
26,
ORmeta = 1.57) with no evidence of heterogeneity between the
two cohorts (Q= 0.94, 1 degree of freedom, I2 = 0). In this region,
5 SNPs showed a difference in allele frequencies at P,561025 in
355 Kbp (Figure 1, Table 1). These SNPs span two genes,
PLEKHA5 and AEBP2. The second strongest association with
no heterogeneity (Q= 0.59, 1 degree of freedom, I2 = 0) was
observed for chromosome 5p13 (rs10512793, Pmeta = 2.7610
26,
ORmeta = 1.61), in which two SNPs, spaced by 196 Kbp, showed a
difference in allele frequencies at P,561025 (Figure 1, Table 1).
These two SNPs were located in the OXCT1 gene, and upstream
to PLCXD3. In order to further explore the associated peak in
these two regions, we used a three-SNP sliding window and
performed a haplotype analysis. Whereas no further significant
difference, as compared to single SNP analysis, was observed on
chromosome 12p12, a more significant difference between patients
and controls was observed on chromosome 5p13 for the
combination of rs624097-rs316762-rs10512793, for which an
overall Pmeta = 2.6610
27 was observed (Figure 1).
Imputation data
In order to refine the association signal in these two regions, we
imputed data for ungenotyped SNPs in the French and the
German cohorts based on the 3.9 million SNPs genotyped in the
CEU population of the HapMap project. The results of the two
populations were then combined to perform an association study.
After imputation, we observed an increased signal for chromosome
12 with the lowest estimated P-value for rs10743315
(P=2.161027, OR=1.61) located in PLEKHA5 (Figure 1). On
the contrary for chromosome 5, the lowest P-value was observed
for the genotyped SNP, rs10512793.
Replication studies on the WTCCC and the GAIN-TGen
cohorts
We analysed the top-16 SNPs (P,561025) out of the meta-
analysis in two additional samples of early-onset bipolar patients,
already genotyped on different platforms through the WTCCC
and the GAIN and performed a mega-analysis including the four
samples (Table S3 in File S2). Only 4 SNPs, genotyped in a
subsample of 764 early-onset bipolar patients and 2,938 matched
Genetics of Early-Onset Bipolar Disorder
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controls from the United Kingdom out of the WTCCC, were
either directly or in strong linkage disequilibrium (r2.0.99) with
SNPs genotyped in the WTCCC sample. None of them showed a
nominal P-value (P,0.05). However, two SNPs on chromosome
5p13 in lower linkage disequilibrium (r2 = 0.65) with rs822135
showed a nominal P-value (rs625487, P=0.02, OR=1.15 and
rs633407, P=0.02, OR=1.15) (data not shown). Both were
located approximately 55 Kbp upstream to PLCXD3 and 165
Kbp downstream to OXCT1. In addition, one SNP (rs2565666),
located on chromosome 12p12, 21 Kbp downstream to PLE-
KHA5 and 42 Kbp upstream to AEBP2, also showed a nominal
P-value (rs2565666, P=0.03, OR=1.22) (data not shown). We
Figure 1. Genome-wide association results and detailed peak association regions. (A) Manhattan plot of the meta-analysis performed on
early-onset bipolar patients and controls from France and Germany. Physical position is shown along the x axis and –log10(P-value) is shown along
the y axis. (B) Detail of the two most associated regions on chromosomes 5p13 and 12p12. Allele frequency differences are represented by –log10(P-
values) for the French (open grey circles), the German (open grey squares) and the meta- (open red diamonds) analyses. Grey crosses represent –
log10(P-value) for imputed ungenotyped SNPs. The most associated SNP for each region is shown with orange circle. On chromosome 12p12, the
lowest P-value (P=2.161027) was observed for an imputed SNP (rs10743315). On chromosome 5p13, the lowest P-value (P=2.661027) was observed
for a three-SNPs window haplotype (light blue line) located downstream to OXCT1 and upstream to PLCXD3 (rs624097-rs316762-rs10512793). The
genome-wide significant threshold (P= 561028) is indicated by the blue dash line and the dot black line shows a threshold at P=561025. The largest
differences in allele frequencies are represented with filled diamonds. Gene position and annotation (http://genome.ucsc.edu/) are symbolised by
green arrows. Linkage disequilibrium (r2) estimated according to HapMap CEU population SNPs (release 3) is symbolised in the bottom part of each
figure. Darker red indicates higher values.
doi:10.1371/journal.pone.0104326.g001
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also compared a sample of 1,524 early-onset bipolar patients with
1,436 controls out of the combined GAIN-TGen cohorts. None
out of the 15 tested SNPs showed a nominal P-value (Table S3 in
File S2). The mega-analysis showed a high heterogeneity between
the samples from France and Germany and the two samples from
U.K. and U.S.A. This analysis resulted in a low signal on
chromosomes 5p13 and 12p12 (rs10512793, Pmega=5.05610
22,
ORmega = 1.38 and rs3752823, Pmega=5.79610
22, OR-
mega = 1.43, respectively). The strongest association observed in
the mega-analysis for SNPs tested in at least three of the four
populations was observed on chromosome 7q36.3 in a gene desert
(rs4716990, Pmega=3.78610
22, ORmega = 1.25).
Structural abnormalities in region of interest
Fluorescence level of genotyped SNPs was only available for a
subsample of early-onset patients of French and German origin
(N= 321). We analysed this fluorescence level in the two 1.5 Mbp
regions of interest on chromosome 5p13 and 12p12. On
chromosome 5p13, we identified, in a French patient who
manifested a first mood episode by the age of 17, a 90-Kbp
deletion removing the PLCXD3 promoter region as well as the
first coding exon of the gene (Figure 2), whereas no copy number
variation has been previously reported in this region in the
database of genomic variations (http://projects.tcag.ca/variation/).
Although DNA was not available for first-degree relatives of this
patient, the deletion was confirmed using quantitative PCR analysis
(data not shown). In order to determine whether independent family
specific mutations might be frequently found in bipolar patients, we
screened all coding exons of PLCXD3 in 334 French subjects (204
patients with early-onset BD and 130 patients with late-onset BD).
Three synonymous variations (p.V58, p.A130 and p.P251) were
found in these patients, and one amino acid change (p.R93H) was
identified in one subject with early-onset BD type I and obsessive
compulsive disorder. This variation was not found in 293 unaffected
matched controls. This amino acid is highly conserved through
evolution and, according to PolyPhen-2 [37], this variation is
predicted to strongly affect the function of the protein. Further
analysis of the available DNA sample in this family showed that this
variation was transmitted from the father (Figure S3 in File S1). The
patient manifested first mood symptoms by the age of 19. Although
his father did not meet criteria for mood disorder according to
DSM-IV, his first cousin manifested major depressive disorder by
the age of 65. Unfortunately, no DNA was available for this subject.
Discussion
The important clinical heterogeneity of BD has probably
hampered the identification of vulnerability genes so far. After
tumultuous starts, GWA studies have enabled the identification of
robust and replicable genetic findings of weak effect, in regions of
CACNA1C, ODZ4 and NCAN, but without disease specificity [4].
In this study, we conducted a genome-wide approach on a highly
heritable phenotype, focusing on patients with an early age at
onset. Based on the genotyping data of 261,525 SNPs, we did not
identify SNPs that reached the genome-wide significant threshold
in our patients and controls of French origin. This was most likely
due to the small sample size of our cohort. We calculated the
statistical power of our study, using the CaTS software [38] and
estimated that we had 80% chance to detect only SNPs with a
genetic risk factor higher than 1.7 (Figure S4 in File S1). However,
recent data from larger cohort studies showed a polygenic
component in BD [3,39], consistent with a combine vulnerability
resulting from many variants of weak effect. We thus conducted a
replication study on a German cohort of patients with early-onset
BD and performed a subsequent meta-analysis. Although it did
not reach the genome-wide significant threshold, the most
associated region in our meta-analysis was located on chromosome
12p12. This region has been previously associated with bipolar
disorder [40–42] and more specifically when patients had an early
age at onset of mania [40]. Five SNPs in this region showed a
difference in allele frequencies between patients and controls,
spanning two genes, PLEKHA5 and AEBP2. The genetic
refinement using imputed data showed the lowest P-value for a
SNP located in PLEKHA5 (rs10743315, P=2.161027). PLE-
KHA5 encodes a protein containing a pleckstrin homology
domain, which interacts with phosphatidylinositol 3-phosphate
[43]. Few elements are known about this gene except its
ubiquitous pattern of expression, including foetal and adult brains.
Nevertheless, there is compelling evidence for the implication of
the phosphatidylinositol signalling pathway in the etiopathogeny of
BD and the two most effective mood stabilisers for BD (lithium
and valproate) directly inhibit this pathway [44]. Further
exploration of response to mood stabilizer in regards to the
PLEKHA5 genotypes might help in understanding the difference
observed according to the patients’ age at onset [15].
The second most associated region in our meta-analysis was
located on chromosome 5p13. In this region, the highest difference
in allele frequencies between patients with early-onset BD and
controls was observed for rs10512793. This SNP was located in
OXCT1, which encodes a 3-oxoacid CoA transferase 1. This
enzyme catalyzes the reversible transfer of CoA from succinyl-
CoA to acetoacetate and is thus the first step of ketone body
utilization, the main source of lipid-derived energy for the brain
Figure 2. Copy number variation identified on chromosome
5p13. (A) Fluorescence level of SNPs of the region for the deleted
patient visualized using SnipPeep. Red dots represent fluorescence level
of SNPs and green dots correspond to the SNP heterozygocity. (B)
Chromosomal position of the deletion. Gene position and annotation
(http://genome.ucsc.edu/) are symbolised by green arrows. Deletions
reported in the Database of Genomic Variants (http://projects.tcag.ca/
variation/) are represented with blue bars. No duplication has been
reported in this region. A red bar represents the deletion identified in
the patient with early-onset BD.
doi:10.1371/journal.pone.0104326.g002
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[45]. Mutations in this gene are associated with succinyl CoA:3-
oxoacid CoA transferase (SCOT) deficiency, characterised by
episodes of severe ketoacidosis [46,47], which can also emerge
during treatment with some atypical antipsychotics [48]. However,
the haplotype analysis of this region suggested that the associated
peak might be located more likely downstream to OXCT1 and
upstream to PLCXD3. This result is consistent with the 90 Kbp-
deletion reported in one of the French patients and that removed
the promoter region and the first coding exon of PLCXD3.
Further exploration of this gene revealed a mutation predicting to
change the amino acid sequence of the protein (p.R93H) and
transmitted from his father, who had a first cousin with major
depressive disorder. Interestingly, this gene encodes a phosphati-
dylinositol-specific phospholipase C, strengthening the involve-
ment of the phosphoinositide-signalling pathway in vulnerability to
BD. Note that tricyclic antidepressants (e.g. desipramine), which
are known to induce rapid cycling or induce manic or hypomanic
episodes in some patients with BD [49], stimulate phospholipase C
activity and the production of the second messenger inositol 1,4,5-
trisphosphate [50]. In addition, experiments performed using rat
cultured hippocampal neurons revealed that desipramine rapidly
enhanced the spontaneous SNAP25-dependent vesicular release of
glutamate [51]. This Ca2+ dependent mechanism is consistent with
our previously reported association between SNAP25 and early-
onset BD [12] and with the strong associations observed between
SNPs located in CACNA1C and BD [1,3].
The main limitation of our study is not to reach the stringent
genome-wide threshold. Although this might translate an absence
of common genetic variations for a clinical subgroup based on an
early age at onset, this is also a direct consequence of the small
sample size and the loss of power inherent to the subphenotype
analysis. Similar study on larger sample should be performed to
confirm our data and valid the relevance of such approach.
Nevertheless, results observed in our French subsample with an
early age at onset have been replicated in a German sample and
supported by the data from the WTCCC with similar phenotype
criteria.
Another possible cause of the loss of power in our analysis is the
categorical exploration of the age at onset. Despite a widely valid
threshold for the age at onset [16,17,22–25], a continuous
exploration of this variable would allow to determine whether
specific loci might lead to various age at onset, which would result,
under multiplicative or additive models, in an overall early age-at-
onset in patients. Such hypothesis is supported by the recent
observation of the International Schizophrenia Consortium, which
showed the molecular genetic evidence for a substantial polygenic
component to the risk of BD involving thousands of common
alleles of very small effect [39]. Similar analysis should thus be
performed according to the patients’ age at onset, but this should
require larger samples for the study and the replication analysis.
In conclusion, although we did not reach the genome-wide
significant threshold in our association study, we report here
convergent data between our GWA study on early onset BD, the
structural abnormality observed in one patient and a missense
mutation reported in one family with early-onset BD. The
difficulties to reach the stringent genome-wide significant thresh-
old suggest that larger samples should be included, which will also
help in better defining the most convenient strategy to take into
account the age at onset of patients. Although the current
nominally significant findings should be interpreted with caution
and need replication in independent cohorts, our results displayed
that the combined exploration of common and rare variants in BD
can reveal identical pathways suggesting both approaches should
be systematically used in further genetic exploration of this
disorder. Using these approaches, we provided evidence that
variations in phosphoinositide secondary messenger signalling
pathway, and for the first time, that the PLEKHA5 and PLCXD3
genes, might confer vulnerability to early-onset BD. Further
exploration of these mechanisms might be used to better identify
markers of prognosis and help the development of innovative
treatment for these severe forms of the disease.
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